mixed hyperlipidemia

Additionally, in Europe, fenofibrate is indicated in mixed hyperlipidemia in patients with high cardiovascular risk in addition to a statin when triglycerides and HDL are not adequately controlled.

In the United States, it was approved in May 2013 by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet.